Genes Predict Mesothelioma Treatment Response
December 26th, 2011
University of Chicago researchers have released the results of genetic studies they hope will shed some light on why some mesothelioma patients respond well to pemetrexed (Alimta) while others do not. In 2004, pemetrexed was the first medicine approved by the FDA specifically for the treatment of malignant mesothelioma. It has since also been approved for the [...]